NewAmsterdam Pharma (NAMS) Other Non-Current Liabilities (2022 - 2024)

NewAmsterdam Pharma has disclosed Other Non-Current Liabilities across 3 years of filings, most recently posting $18.8 million for Q3 2024.

• Other Non-Current Liabilities for Q3 2024 came in at $18.8 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $18.8 million (changed N/A YoY), and the FY2023 annual result was $7.8 million, up 3.54% from the prior year.
• Other Non-Current Liabilities came in at $18.8 million for Q3 2024 at NewAmsterdam Pharma, up from $13.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $18.8 million in Q3 2024 to a low of $8224.6 in Q2 2023.
• The 3-year median for Other Non-Current Liabilities is $10.6 million (2023), against an average of $10.6 million.
• Across the five-year window, Other Non-Current Liabilities gained 8.23% in 2023 and soared 162752.0% in 2024, its largest moves.
• NewAmsterdam Pharma's Other Non-Current Liabilities stood at $7.2 million in 2022, then rose by 8.23% to $7.8 million in 2023, then soared by 141.5% to $18.8 million in 2024.
• The last three Other Non-Current Liabilities figures came in at $18.8 million (Q3 2024), $13.4 million (Q2 2024), and $16.5 million (Q1 2024), per Business Quant data.